Current and future biomarkers in gastric cancer

Abbas, Muhammad; Faggian, Alessia; Sintali, Dahiru Nasiru; Khan, Ghulam Jilany; Naeem, Shagufta; Shi, Meiqi; Chen, Dingding

doi:10.1016/j.biopha.2018.04.178

Cited by 51 publications

(37 citation statements)

References 177 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consequently, patients with the same tumor stage often exhibit different clinical outcomes (9). There are ongoing research efforts aimed at identifying novel biomarkers to diagnose GC in early stages and to develop more effective therapy monitoring strategies (10).…”

Section: Introductionmentioning

confidence: 99%

“…Biomarkers with a potential use in GC include, among others, E-cadherin, human epidermal growth factor receptor 2 (HER2), fibroblast growth factor receptor, receptor tyrosine kinase MET, human epidermal growth factor receptor, hepatocyte growth factor receptor, mammalian target of rapamycin, microsatellite instability, programmed cell death-ligand 1 and p53 (10,11). However, their beneficial application in the management of GC patients is generally limited.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Diagnostic and prognostic value of circulating lncRNA H19 in gastric cancer

et al. 2018

View full text Add to dashboard Cite

Gastric cancer (GC) is among the most frequent malignant diseases. Despite advances in treatment, the clinical outcome of patients with GC remains poor. The establishment of novel biomarkers is urgently required for early detection, treatment evaluation and prognostic assessment. Non-coding RNAs (ncRNAs) are a key topic of intensive research due to their potential applications in the field of oncology. The long ncRNA H19 has been frequently reported as overexpressed in many cancers including GC. In the present study, the diagnostic and prognostic value of circulating H19 in GC was assessed. Higher levels of circulating H19 were identified in GC patients (n=40) compared with a control group consisting of endoscopy-verified GC-free individuals (n=42; median levels relative to GAPDH, 58.4 vs. 29.9; P=0.027). Patients with smaller tumor sizes (<5 cm) exhibited higher H19 in their circulation compared with those with larger tumors (≥5 cm; P=0.04). Plasma levels of H19 declined significantly upon surgical removal of gastric tumors as documented in a subset of patients [n=20; relative median levels, 146.0 vs. 15.0 (pre-surgery); P=0.003]. However, it was identified that H19 had no prognostic role in GC by the Kaplan-Meier method. In conclusion, the present findings identify H19 as potential diagnostic marker in GC.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Diagnostic and prognostic value of circulating lncRNA H19 in gastric cancer

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Gastric cancer, a leading cause of cancer-related deaths, is a heterogeneous disease with many kinds of subtypes. Mountain evidences show that different subtype of gastric cancers usually possess distinct clinical outcomes [18,19]. In the past, only the coding genes were developed as biomarkers for tumor diagnosis.…”

Section: Discussionmentioning

confidence: 99%

Global miRNA Expression Analysis Identifies miR-194, miR-100, miR-125b and miR-199a as Promising Biomarkers for Gastric Cancer and miR-194 Inhibits Gastric Cancer Cell Growth by Targeting CCND1

Li¹,

Wang²,

Zhang³

et al. 2020

Preprint

View full text Add to dashboard Cite

BackgroundDifferent gastric cancer (GC) subtypes usually possess distinct clinical outcomes. The function of miR-194 in gastric cancer remains unclear and controversial. This study aimed to identify potential microRNAs that differentially expressed in subtypes and to elucidate the molecular mechanisms of miR-194 in GC.MethodsComprehensive miRNA expression analysis was performed using the available miRNA-seq data from TCGA stomach cancer cohort. The preferences of miR-194 in regulating target genes were determined by RNA sequencing studies. The function of miR-194 in GC was explored in GC cell lines by performing qRT-PCR assays, western blot assays, cell proliferation assays, luciferase report assays and flow cytometry assay.ResultsIn this study, we identified a series of miRNAs that can serve as prognostic biomarkers for GC. Among them, miR-100, miR-125b, miR-199a and miR-194 were the 4 most promising prognostic biomarkers in GC due to their significant associations with various clinical characteristics of patients. MiR-100, miR-125b and miR-199a predicted poor prognosis in GC, while miR-194 predicted favorable prognosis in GC. Besides, we provided the first comprehensive transcriptome analysis about miR-194 in GC. The results showed that miR-194 tended to regulated target genes by binding on their 3' untranslated regions in a 7-mer-A1 or 7-mer-m8 or 8-mer manner. The KEGG pathway analysis showed that cell cycle was one of the most affected pathways by miR-194 in GC. Moreover, CCND1 was proved to be a novel target gene of miR-194 in GC. Additionally, the downregulation of CCND1 by miR-194 in GC further led to cell growth inhibition and cell cycle arrest. ConclusionsMiR-100, miR-125b, miR-199a and miR-194 could serve as prognostic and diagnostic biomarkers for GC. MiR-194 might suppress GC cell growth mainly through targeting CCND1 and induction of cell cycle arrest.

show abstract

“…Developing an appropriate non-invasive biomarker might help in the diagnosis and prognostication of GC [17]. In that manner vascular endothelial growth factor (VEGF), human epidermal growth factor receptor (HER) family, E-cadherin, programmed death-ligand 1(PD-L1) and programmed death-ligand 2(PD-L2), fibroblast growth factor receptor(FGFR), mammalian target of rapamycin(mTOR), are among the emerging biomarkers due to the variations in MET, MSI and microRNA [18].…”

Section: Serum Based Biomarkermentioning

confidence: 99%

Unveiling the Genomic Landscape of Gastric Cancer Diagnosis, a Snapshot

Uthansingh¹,

Agarwala²,

Sahu³

2020

Act Scie Canbio

View full text Add to dashboard Cite

Gastric cancer (GC) still one of the most prevalent malignancies across the globe. So far, the majority of research studies have not come up with a proper diagnostic and therapeutic approach which may be due to lack of external validation. Attempts have been undertaken but due to methodological shortcomings and insufficient reporting, the breach between biomarker discovery and its clinical use not been explored. So, there should be an improved systematized tunnel of diagnostic marker approach focusing on correct methodology, quality of support, and emphasis on external validation which could have an impact on better clinical diagnosis and prognostication. This review aimed at the early diagnosis of GC through biomarkers and their potential applications in cellular proliferation, apoptosis, and angiogenesis. Moreover, this review highlights the genetic, epigenetic modifications, signaling pathways, and NGS advancement that could identify the novel therapeutic targets as well as noninvasive biomarkers for therapeutic response.

show abstract

Current and future biomarkers in gastric cancer

Cited by 51 publications

References 177 publications

Diagnostic and prognostic value of circulating lncRNA H19 in gastric cancer

Diagnostic and prognostic value of circulating lncRNA H19 in gastric cancer

Global miRNA Expression Analysis Identifies miR-194, miR-100, miR-125b and miR-199a as Promising Biomarkers for Gastric Cancer and miR-194 Inhibits Gastric Cancer Cell Growth by Targeting CCND1

Unveiling the Genomic Landscape of Gastric Cancer Diagnosis, a Snapshot

Contact Info

Product

Resources

About